Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus METHYLPREDNISOLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus METHYLPREDNISOLONE.
BREO ELLIPTA vs METHYLPREDNISOLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Glucocorticoid receptor agonist; inhibits phospholipase A2, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell activity.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
4-48 mg/day orally in divided doses; 10-40 mg IV/IM bolus, then 10-40 mg IV q4-6h; high-dose IV pulse: 1 g/day for 3 days.
None Documented
None Documented
Clinical Note
moderateMethylprednisolone + Digoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethylprednisolone + Digitoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethylprednisolone + Deslanoside
"Methylprednisolone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethylprednisolone + Acetyldigitoxin
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Plasma: 2.5-3.5 hours; biological half-life (tissue): 18-36 hours due to glucocorticoid receptor-mediated effects; clinical context: anti-inflammatory effects persist beyond plasma clearance
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal (primarily as inactive metabolites, <10% unchanged); minor biliary/fecal elimination
Category C
Category D/X
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid
"Methylprednisolone may decrease the cardiotoxic activities of Acetyldigitoxin."